This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Management of Refractory/Relapsed ALL video

Speaker: Professor David Marks

Duration: 07:34

In this video, Professor Marks discusses the goals of treatment for relapsed/refractory acute lymphoblastic leukaemia patients in the INO-VATE study:

  • Key outcomes from the INO-VATE1 study: BESPONSA vs. standard chemotherapy
  •  Long term follow up2
  •  How to approach haematopoietic bone marrow transplant post BESPONSA
  •  Veno-occlusive disease risk analysis assessment before considering BESPONSA treatment
  • Reducing risks of veno-occlusive disease during treatment with BESPONSA

David Marks is Professor in Haematology and Stem Cell Transplantation and Director of
the Bristol Bone Marrow Transplant (BMT) Unit. He additionally holds an Honorary Senior Lectureship at the University of Bristol. He received his medical education at the University of Melbourne, Australia, and his clinical training at the Royal Melbourne Hospital, before undertaking positions in London, UK, and Philadelphia, PA, USA. He was appointed as a Consultant at the Bristol BMT Unit in 1996.

David’s research and scientific papers focus on clinical aspects of stem cell transplantation,
acute lymphoblastic leukaemia (ALL) and infection. In 1999, he worked to initiate the Clinical
Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT), the
first national transplant trial group. He chaired the group for 5 years and was President of
BSBMT from 2007 to 2009. From 2012 to 2015, he was European Vice Chair of the Advisory Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), and in 2017, he was the CIBMTR Chair of the Tandem BMT meetings in Orlando, FL, USA.
Since 2016, he has been Medical Director of IMPACT, the UK transplant trials platform. He is currently Transplant Coordinator and Deputy Chair of the National Cancer Research Institute ALL Working Group, Chair of the Adjudication Committee of BSBMT and a member of the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

He has authored numerous scientific papers and chaired the ALL education session at the American Society of Hematology meeting in 2010.

Explore more

Developments in Leukaemia Care

Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival

Learn More

Key data from the INO-VATE study

Hear Dr. Anna Castleton discuss the key data for BESPONSA vs standard care from the INO-VATE study

Learn More

SmPC, Summary of product characteristics
 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References:
  1. Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.
  2. Kantarjian HM, et al. Cancer 2019;125;2474–2487
PP-INO-GBR-0515. August 2021

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. March 2021

Sign up now

Fast Facts

Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.

Download here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No